Oxford Immunotec Announces New Initiative to Bring the Benefit of Modern Tuberculosis Testing to the Russian Federation
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced a new local production initiative to bring the benefits of the T-SPOT®.TB test to the Russian Federation.
Since the T-SPOT.TB test received approval in the Russian Federation in 2013, Oxford Immunotec has been working with a local distribution partner, PharmLine LLC (“PharmLine”) and has seen expanding uptake of the T-SPOT.TB test. In collaboration with PharmLine, Oxford Immunotec will now also be working with Generium Joint Stock Company (“Generium”), who will be manufacturing the T-SPOT.TB test locally at their factory in the Vladimir region of the Russian Federation. This is expected to reduce the cost of, and expand access to, the T-SPOT.TB test for patients in the Russian Federation. Additionally, Generium will be working with PharmLine on marketing and distribution of the T-SPOT.TB test, including applying for national TB control tenders.
The Russian Federation is among the 20 countries worldwide with the highest estimated numbers of incident TB cases, with a reported incidence rate of 60 cases per 100,000 population and a high rate of HIV/TB coinfection.1 The Russian Federation has the 3rd highest rate of multi-drug resistant TB in the world,2 which adds urgency to the need to reduce TB rates before drug resistance undermines the ability to successfully treat those diagnosed. With a strong commitment to new actions to end TB, the WHO and the Government of the Russian Federation convened the First WHO Global Ministerial Conference, Ending TB in the Sustainable Development Era: A Multisectoral Response, which was a fundamental milestone towards the United Nations General Assembly (UNGA) High-Level Meeting on TB in 2018. The development and implementation of more ambitious, fully-funded national TB policies and strategic plans is also one of many commitments included in the Moscow Declaration to End TB.3
The WHO and the UN have both recognized that a critical component in the fight to end TB is the rapid scaling up of access to and testing for TB infection in high-burden countries, particularly focusing on those most at risk of falling ill, such as children and those with HIV.4 They have also called on stakeholders to develop new models to increase access to the tools, such as interferon gamma release assays (IGRA) tests,5 which are now included in the WHO’s List of Essential In Vitro Diagnostics.6
“This new development allows Generium to bring into Russia a high-precision laboratory test for the diagnosis of tuberculosis infection, with the economic benefits of local production,” said Dmitriy Kudlay, CEO of Generium. “Together with PharmLine and Oxford Immunotec we are excited to expand the use of the T-SPOT.TB test in Russia in order to support the state’s aims in ending TB in the country.”
“We are very pleased to enter into this exciting new approach with Generium, who as the skin test providers in Russia, have unparalleled reach and relationships within Russia and Kazakhstan,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. “We believe working with PharmLine and Generium expands the reach of the T-SPOT.TB test and we are proud to take another step forward in helping the clinical community in Russia in their fight against TB.”
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company's T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
Generium is the leading Russian biopharmaceutical company, focused on developing and commercializing diagnostic systems and pharmaceutical products for the treatment of orphan diseases, infection diseases, cancer, multiple sclerosis, myocardial infarction and strokes as well as tuberculosis diagnostic test - Diaskintest®. Generium consists of a high-end R&D center and a fully integrated manufacturing plant. Generium has more than 30 innovative products in the pipeline, including enzymes, monoclonal antibodies and ATMPs. Generium is headquartered in Moscow, Russia. Additional information can be found at www.generium.ru/en.
Diaskintest is a trademark of Generium Joint Stock Company.
PharmLine was founded in 1993 and is a leading healthcare product distributor. PharmLine specializes in the marketing and sales of pharmaceuticals, diagnostic products and technologies for hospital and laboratory use in the Russian Federation and the Confederation of Independent States. PharmLine is located in Moscow, Russia.
This release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this release are forward-looking statements. This includes statements about Oxford Immunotec's anticipated plans and objectives, future performance and revenues, financial condition, prospects for sales of its products, growth, strategies, expectations and objectives of management. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements contained in this release reflect Oxford Immunotec's current expectations and are subject to risks and uncertainties. Actual results may differ materially from those projected or implied by forward-looking statements. Other factors that could adversely affect Oxford Immunotec's business and prospects are described under the "Risk Factors" section in its filings with the Securities and Exchange Commission ("SEC"). Oxford Immunotec's SEC filings are available for free by visiting the investor section of its website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
VP, Strategy & Investor Relations
Tel: +1 (508) 556-1377
The Head of International Department
Tel: +7 (495) 988-47-94 ext. 7073
Tel: +7 (495) 988-47-94 ext. 7020
1 Global tuberculosis report 2018 (35). WHO; 2018
2 Global tuberculosis report 2018 (49). WHO; 2018
3 Moscow Declaration to End TB; First WHO Global Ministerial Conference on Ending TB in the Sustainable Development Era: A Multisectoral Response, November 2017. WHO and the Ministry of Health of the Russian Federation; 2017
4 Resolution adopted by the General Assembly on 10 October 2018: 73/3 Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis (5 – 6). United Nations General Assembly; 2018
5 Resolution adopted by the General Assembly on 10 October 2018: 73/3 Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis (10). United Nations General Assembly; 2018
6 World Health Organization Model List of Essential In Vitro Diagnostics – First Edition (2018). WHO; November 2018
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Oxford Immunotec Appoints Patrick J. Balthrop, Sr. as Chairman24.6.2019 17:35:00 CEST | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it has appointed Patrick J. Balthrop, Sr. as Chairman of its board of directors. The current Chairman, Mr. Richard A. Sandberg, will remain a member of the board. “On behalf of the Company and the board of directors I would like to thank our former Chairman, Richard Sandberg, for his service,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. “In the decade that he served as Chairman, the Company has undergone a profound transformation, and Mr. Sandberg’s guidance and leadership has made an extraordinary contribution to Oxford Immunotec’s success. We look forward to continuing to benefit from his skills and his knowledge of the Company with his ongoing service as a Non-Executive Director.” “We are very pleased to have Mr. Balthrop assume the role of Chairman,” continued Dr. Wrigh
Woodbridge by Robert Mondavi Announces New Transformative Brand Positioning24.6.2019 15:50:00 CEST | Pressemelding
“From One For All” National Campaign Brings Brand’s Pioneering Spirit to the Forefront of Story and Marks a Number of Brand Firsts LODI, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- Woodbridge by Robert Mondavi, the number-three wine brand in the United States* with 40 years of history dedicated to raising the standard for everyday wines in America and globally, announces a new milestone with the launch of its new national brand campaign. The “From One For All” campaign celebrates Woodbridge founder Robert Mondavi’s pivotal role in democratizing wine. It is supported by a 360-degree integrated marketing plan backed by the largest investment in the brand’s history. For the first time, Woodbridge by Robert Mondavi tells the winery’s powerful founding story and industry-changing vision through the lens of its iconic founder Robert Mondavi in the new “From One For All” marketing campaign. Celebrated for his achievements helping to establish California’s reputation for fine winemaking on a glo
Sanan IC Expands Wafer Foundry Portfolio for Power Electronics with 150mm GaN-on-Silicon Process24.6.2019 15:00:00 CEST | Pressemelding
SUNNYVALE, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- SANAN INTEGRATED CIRCUIT CO., LTD. (Sanan IC), a pure-play wafer foundry with its advanced compound semiconductor technology platform, today announced the commercial release of its 150mm gallium nitride (GaN) on silicon wafer foundry services intended for the latest high voltage AC/DC and DC/AC power electronics applications in the global market. Sanan IC’s new G06P111 is a 650V enhanced-mode high-electron-mobility transistor (E-HEMT) GaN process which adds to the company’s power electronics wafer foundry portfolio of wide bandgap (WBG) compound semiconductors that includes 100mm and 150mm silicon carbide (SiC) for high voltage Schottky Barrier Diodes (SBD). Leveraging years of high volume GaN manufacturing experience by Sanan Optoelectronics Inc., its parent company, for the LED market, Sanan IC is able to complement its foundry services with in-house MOCVD growth capabilities of high voltage, low leakage GaN-on-silicon epitaxial wa
Nasdaq Promotes Tal Cohen to Executive Vice President, North American Market Services24.6.2019 14:30:00 CEST | Pressemelding
Tom Wittman to become Executive Advisor and to retire from Nasdaq at year-end NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. today announced it has named Tal Cohen as Executive Vice President, North American Market Services, effective July 1. In this role, Cohen will be responsible for driving the strategy and success of our trading businesses across cash equities, commodities, derivatives, and trade management services in Nasdaq’s U.S. and Canadian markets. In his role, in addition to directing the strategy of the business, Cohen will oversee Nasdaq’s North American trading products across their lifecycle and will manage client relationships and market operations. He will report to Adena Friedman, President and CEO, Nasdaq. Cohen joined Nasdaq in April 2016 as Senior Vice President of North American Equities following the acquisition of Chi-X Canada, where he had served as CEO of Chi-X Global Holdings for six years. Prior to Chi-X, Cohen held senior positions at Instinet, Am
U.S. Army awards Vricon contract for One World Terrain24.6.2019 14:30:00 CEST | Pressemelding
Vricon to apply its Globe in 3D solution to support military training anywhere in the world McLean, VA, June 24, 2019 (GLOBE NEWSWIRE) -- Vricon is pleased to announce that on 14 June 2019, the U.S. Army, working through the Training and Readiness Accelerator, awarded Vricon an Other Transaction Agreement to build One World Terrain (OWT). One of the key objectives of OWT is to provide an accurate and realistic 3D global terrain that replicates the military’s operational environment. Specifically, OWT is part of the Synthetic Training Environment's Common Synthetic Environment (CSE). The CSE is the platform enabler of the Synthetic Training Environment that will allow units and soldiers to conduct realistic, multi-echelon collective training anywhere in the world. The Common Synthetic Environment is composed of three foundational capabilities: One World Terrain, Training Management Tool, and Training Simulation Software. “We are honored that the Army chose the Vricon solution for its On
WorkForce Software Announces Strategic Growth Investment from Evergreen Coast Capital24.6.2019 14:00:00 CEST | Pressemelding
Investment to Accelerate WorkForce Software’s Global Expansion and Commitment to Customer-First Innovation LIVONIA, Mich., June 24, 2019 (GLOBE NEWSWIRE) -- WorkForce Software®, a leading global provider of cloud-based workforce management solutions, announced today a significant equity investment from affiliates of Evergreen Coast Capital Corp. (“Evergreen”), the technology-focused private equity arm of Elliott Management Corporation. With the investment, Evergreen will become equal partners with Insight Partners, which has been the majority investor in WorkForce Software since 2014. Terms of the transaction were not disclosed. Founded in 1999, WorkForce Software is making work easy for the connected workforce around the globe. The company’s cloud-based solutions enable enterprise and mid-sized organizations to digitize time and attendance processes, optimize employee scheduling, simplify absence management, and gain strategic business insights. WorkForce Software was the first workfo